U.S. Markets open in 7 hrs 56 mins

Incyte shares should be bought on weakness, says JMP Securities

After Incyte COO Pat Andrews left the company, JMP Securities doesn't anticipate that this development will have any long-term implications on the outlook for the company's myelofibrosis treatment, Jakafi. The firm reiterates an Outperform rating on the stock.